Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has issued an update.
Shandong Xinhua Pharmaceutical Company Limited has released its unaudited financial results for the first quarter of 2025, showing a slight decrease in operating income by 1.81% compared to the same period last year. The company reported a significant decline in net profit attributable to shareholders, down by 20.99%, and a substantial drop in net cash flow from operating activities by 77.87%. Despite these challenges, the company’s total assets increased by 2.77%, and net assets attributable to shareholders rose by 3.28%, indicating a stable asset base.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a joint stock company based in China, primarily engaged in the pharmaceutical industry. The company focuses on the production and distribution of pharmaceutical products and related services.
YTD Price Performance: -3.10%
Average Trading Volume: 2,170,030
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.56B
See more data about 0719 stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “Losing the Console Race by Miles”: Microsoft Stock (NASDAQ:MSFT) Ticks Up as the Console Wars Gain a Bit of Clarity
- “…In 18 Months This is a $35,000 Truck” Tesla Stock (NASDAQ:TSLA) Surges With New Pricing Projections
- “Historic Union Busting”: Starbucks Stock (NASDAQ:SBUX) Slips as Strikes Gain Ground, Draw Congress Reps